LONZA GROUP AG UNSP ADR EACH REP 0.1 ORD Stock Forum

The pharma giant $Eli Lilly and Co (LLY.US)$ is on the cusp of a significant breakthrough with its Alzheimer's drug, donanemab. Following the completion of its Phase 3 trials, donanemab is currently undergoing FDA review and has the potential to receive approval later this month. If approved, it would be the second anti-Aβ therapy for Alzheimer's disease to receive full clearance from the U.S. FD...